Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research trial studies the levels of a type of biomarker, circulating tumor cells (CTCs), in the blood of patients with stage I-IV melanoma. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Studying samples of blood in the laboratory obtained before and after treatment from patients with melanoma may help doctors learn more about changes that occur in CTC levels and whether they may predict how well patients will respond to therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

In Vivo Real-time Detection of Circulating Melanoma Cells

NCT01776905

Melanoma

RECRUITING

Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery

NCT01886235

Recurrent Melanoma Stage IA Skin Melanoma Stage IB Skin Melanoma +7 more

COMPLETED NA

Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients

NCT02744209

Stage IV Melanoma

TERMINATED

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

NCT04928365

Melanoma

UNKNOWN PHASE2

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

NCT05628883

Metastatic Melanoma Unresectable Melanoma Acral Melanoma +7 more

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Specimen Collection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must have signed tissue collection consent as described in protocol IRB# 703001,UPCC# 08607, PI: Giorgos Karakousis, MD
* Subjects must be competent to consent for themselves.
* Subjectsmust be adult (18 years or older).
* Subjects must be initiating a new therapy for melanoma (so a pretreatment CTC count can be obtained).